Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

Also called NCT03592823

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03592823
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03592823. Randomized; double masking; primary purpose prevention. Start 2018-08-01 (anticipated); primary completion 2019-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence
Intervention (Drug)
Hydroxychloroquine Sulfate 200 Mg Tablet
Lead sponsor
First Affiliated Hospital of Harbin Medical University (class: other)

Record details

Record id
cardio:ct-nct03592823
Content hash
f7342b1399810d48025f72e384af5199c3c1e304d517e9c8f0fc8d5f661f709e